Vico de Crecchio
Naples, Italy, 80100
Location status: Recruiting
NCT Number: NCT06851676
This clinical study investigates the effects of Fonte Fausta® water on bone and muscle metabolism, as well as quality of life, in patients with osteoporosis or osteopenia, with or without sarcopenia. Conducted as a multicenter, triple-arm trial, it evaluates functional and biochemical markers over 12 months. Patients are randomized into groups receiving either Fonte Fausta® or standard mineral water, with assessments including laboratory tests, bioimpedance analysis, physical and nutritional evaluations, bone density measurements, and quality of life surveys.
Interested in participating?
Request Info65 year and older
All sexes
Interventional
Not applicable
Naples, Italy, 80100
Location status: Recruiting
This study aims to determine the impact of Fonte Fausta® water on bone and muscle metabolism in patients with osteoporosis or osteopenia, with or without sarcopenia, over a 12-month period. The research follows ethical guidelines (Helsinki Declaration) and has been approved by the Ethics Committee of the University of Campania "Luigi Vanvitelli." All participants provided informed consent.
Study Design and Participants The study is a multicenter, triple-arm interventional clinical trial conducted at the University of Campania "Luigi Vanvitelli." Participants include individuals diagnosed with primary osteoporosis or osteopenia, with or without sarcopenia, based on clinical guidelines and the EWGSOP2 criteria. Osteoporosis is diagnosed by a BMD T-score ≤ -2.5 SD or the presence of a fragility fracture, while osteopenia is defined as a BMD T-score between -1 and -2.5 SD. Sarcopenia diagnosis is based on low muscle strength and low muscle mass.
Exclusion criteria
include secondary osteoporosis causes (e.g., chronic diseases, endocrine disorders, long-term corticosteroid use), psychiatric conditions affecting consent, and pregnancy or breastfeeding.
Study Groups and Randomization
Participants are divided into three primary groups:
Patients with osteoporosis/osteopenia and sarcopenia Patients with osteoporosis/osteopenia without sarcopenia A control group with non-osteometabolic conditions
Each group is further randomized into two subgroups:
One receiving Fonte Fausta® water One receiving natural mineral water Assessments and Evaluations
Participants undergo evaluations at three time points:
Baseline (T0) Six months (T6) Twelve months (T12)
Key assessments include:
Laboratory Tests: Blood and urine analyses to assess biochemical markers such as ALP, bone-specific ALP, PTH, 25(OH)D3, and CTX.
Bioimpedance Analysis (BIA): Measures body composition, including fat and muscle mass.
Physical and Nutritional Assessments: Includes questionnaires like the International Physical Activity Questionnaire, handgrip strength measurements, and the Mini Nutritional Assessment.
Bone Health and Fall Risk: DXA scans measure BMD, and the FRAX® algorithm estimates fracture risk.
Pain, Performance, and Quality of Life: Evaluations include the Short Physical Performance Battery (SPPB), Brief Pain Inventory (BPI), and quality of life questionnaires (EQ-5D-3L and EQ-VAS).
This study aims to determine whether Fonte Fausta® water offers functional and metabolic benefits for bone and muscle health, potentially improving quality of life and reducing fracture risk in osteoporotic and osteopenic patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
-a diagnosis of primary osteopenia or osteoporosis , with or without sarcopenia, based on the latest clinical practice guidelines and EWGSOP2 criteria .
Exclusion criteria
Fonte Fausta® water is a natural mineral water, rich in essential minerals, such as calcium, magnesium, and bicarbonate, which are important for maintaining bone density, muscle function, and overall metabolic health.
a natural mineral commercially available
Time frame: 0 (T0), 180 (T1), and 365 days (T2)
Bioimpedance Analysis (BIA) is a non-invasive method used to assess body composition, including fat mass, muscle mass, and total body water. It works by measuring the resistance of electrical currents as they pass through the body's tissues, with lean tissues (muscle and water) conducting electricity better than fat tissues.
Time frame: 0 (T0), 180 (T1), and 365 days (T2)
Blood samples (20 ml), a 24-hour urine collection, and early morning urine analyses will be conducted to evaluate key biochemical markers, including ALP, bone-specific ALP, PTH, 25(OH)D3, CTX, among others.
Contact information is provided by the study sponsor or research team.
ANTIMO
Other
Functional and Metabolic Effects of Fonte Fausta® Water on the Musculoskeletal System in Patients with Osteoporosis/Osteopenia with or Without Sarcopenia
Acronym: FOCUS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04122638
Atrophy, Bone Diseases
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT06018467
Age-related Bone Loss, Bone Diseases
Odense, Denmark
View Trial DetailsNCT04708886
Bone Diseases, Bone Diseases, Metabolic
Chicago, Illinois, United States
View Trial DetailsNCT06812195
Bone Diseases, Bone Diseases, Metabolic
View Trial Details